Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.37 per share, beating the Zacks Consensus Estimate of $5.13 per share. This compares to earnings of $5.15 per share a year ago.
Thermo Fisher on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials.
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.
Stocks tend to sell off after they reach resistance. They also tend to rally off of support.
Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.
Investors with an interest in Medical - Instruments stocks have likely encountered both Thermo Fisher Scientific (TMO) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
Thermo Fisher (TMO) announces the opening of NanoPort, the company???s first electron microscopy demo center in Taiwan, strategically located in the region?
Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.
Thermo Fisher (TMO) has launched biobased solutions to help reduce the climate impact on the manufacturing of therapies.
Thermo Fisher (TMO) announces expansion of its central laboratory operations in Kentucky. The new space in Covington will be in addition to its existing central lab in Highland Heights.
Thermo Fisher (TMO) introduces the Thermo Scientific KingFisher PlasmidPro, the fully automated maxi-scale pDNA purification system.